Osilodrostat (INN, USAN) (developmental code name LCI-699) is an orally active, nonsteroidal corticosteroid biosynthesis inhibitor which is under development by Novartis for the treatment of Cushing's syndrome and pituitary ACTH hypersecretion (a specific subtype of Cushing's syndrome). It specifically acts as a potent and selective inhibitor of aldosterone synthase (CYP11B2) and at higher dosages of 11β-hydroxylase (CYP11B1). The drug was also under development for the treatment of heart failure, hypertension, and solid tumors, but development was discontinued for these indications. As of 2017, osilodrostat is in phase III and phase II clinical trials for treatment of pituitary ACTH hypersecretion and Cushing's syndrome, respectively.

Property Value
dbo:abstract
  • Osilodrostat (INN, USAN) (developmental code name LCI-699) is an orally active, nonsteroidal corticosteroid biosynthesis inhibitor which is under development by Novartis for the treatment of Cushing's syndrome and pituitary ACTH hypersecretion (a specific subtype of Cushing's syndrome). It specifically acts as a potent and selective inhibitor of aldosterone synthase (CYP11B2) and at higher dosages of 11β-hydroxylase (CYP11B1). The drug was also under development for the treatment of heart failure, hypertension, and solid tumors, but development was discontinued for these indications. As of 2017, osilodrostat is in phase III and phase II clinical trials for treatment of pituitary ACTH hypersecretion and Cushing's syndrome, respectively. (en)
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-06-14 20:34:59Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 54246592 (xsd:integer)
dbo:wikiPageLength
  • 3544 (xsd:integer)
dbo:wikiPageModified
  • 2018-11-07 04:25:30Z (xsd:date)
dbo:wikiPageOutDegree
  • 30 (xsd:integer)
dbo:wikiPageRevisionID
  • 867656325 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdfs:comment
  • Osilodrostat (INN, USAN) (developmental code name LCI-699) is an orally active, nonsteroidal corticosteroid biosynthesis inhibitor which is under development by Novartis for the treatment of Cushing's syndrome and pituitary ACTH hypersecretion (a specific subtype of Cushing's syndrome). It specifically acts as a potent and selective inhibitor of aldosterone synthase (CYP11B2) and at higher dosages of 11β-hydroxylase (CYP11B1). The drug was also under development for the treatment of heart failure, hypertension, and solid tumors, but development was discontinued for these indications. As of 2017, osilodrostat is in phase III and phase II clinical trials for treatment of pituitary ACTH hypersecretion and Cushing's syndrome, respectively. (en)
rdfs:label
  • Osilodrostat (en)
foaf:isPrimaryTopicOf
owl:sameAs
is foaf:primaryTopic of